Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (03/28/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Mycosis Fungoides (MF) (Including Sézary Syndrome [SS])

Revised text to state that there is consensus that patients with SS have a poor prognosis, with or without the typical generalized erythroderma (cited Thompson et al. as reference 23).

Added text to state that folliculotropic mycosis fungoides (FMF) is a variant of MF marked by folliculotropic, rather than epidermotropic, neoplastic infiltrates, with preferential location in the head and neck area. Early plaque-stage FMF have a very indolent prognosis, while extracutaneous disease portends a very poor prognosis (cited van Santen et al. as reference 28).

Stage Information for Mycosis Fungoides (Including Sézary Syndrome)

An editorial change was made to this section.

Treatment Option Overview for MF (Including SS)

Added Trautinger et al. as reference 2.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Key References for Mycosis Fungoides (Including Sézary Syndrome)

Next section >
About This PDQ Summary